EXEL - Exelixis gains as Cabometyx patent trial ends
2023-10-26 11:27:48 ET
More on Exelixis
- Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade)
- Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck
- Exelixis: Long-Term Problem Isn't Shareholder Activism - It's Cabo Patent Expiry
- Exelixis slumps amid Cabometyx patent trial (update)
- Exelixis reports positive results for Cabometyx in treating neuroendocrine tumors
For further details see:
Exelixis gains as Cabometyx patent trial ends